Entyvio Dosage

Intravenous Administration for UC and CD

• ENTYVIO should be administered by a healthcare provider prepared to manage hypersensitivity reactions including anaphylaxis, if they occur [see Warnings and Precautions (5.1)]. Appropriate monitoring and medical support measures should be available for immediate use. Observe patients during infusion and until the infusion is complete.
• Reconstitute and dilute ENTYVIO lyophilized powder prior to administration as a 30-minute intravenous infusion [see Dosage and Administration (2.4)].

​Subcutaneous Injection for UC

• ​ENTYVIO prefilled syringe and ENTYVIO PEN are intended for subcutaneous use under the guidance and supervision of a healthcare professional.
• ​Patients or caregivers may self-inject subcutaneous ENTYVIO using either the ENTYVIO prefilled syringe or ENTYVIO PEN after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of ENTYVIO.

Intravenous Infusion

• Week 0: Administer 300 mg by intravenous infusion over approximately 30 minutes [see Dosage and Administration (2.4)].
• Week 2: Administer 300 mg by intravenous infusion over approximately 30 minutes.
• Week 6 and thereafter: Administer 300 mg by intravenous infusion over approximately 30 minutes and then every eight weeks thereafter.
• Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.

​Subcutaneous Injection

• ​Following the first two ENTYVIO intravenous doses administered at Week 0 and Week 2, ENTYVIO may be switched to subcutaneous injection at Week 6.
• ​Week 6 and thereafter: Administer 108 mg subcutaneously once every 2 weeks.
• ​Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.
• ​ENTYVIO may be switched from intravenous infusion to subcutaneous injection, for patients in clinical response or remission beyond Week 6. To switch patients to ENTYVIO subcutaneous injection, administer the first subcutaneous dose in place of the next scheduled intravenous infusion and every two weeks thereafter.

Intravenous Infusion

• Week 0: Administer 300 mg by intravenous infusion over approximately 30 minutes [see Dosage and Administration (2.4)].
• Week 2: Administer 300 mg by intravenous infusion over approximately 30 minutes.
• Week 6 and thereafter: Administer 300 mg by intravenous infusion over approximately 30 minutes and then every eight weeks thereafter.
• Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.

Reconstitution Instructions

1. Remove the flip-off cap from the single-dose vial and wipe with alcohol swab. Reconstitute ENTYVIO vial containing lyophilized powder with 4.8 mL of Sterile Water for injection, 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection, at room temperature (20°C to 25°C [68ºF to 77ºF]), using a syringe with a 21- to 25- gauge needle.
2. Insert the syringe needle into the vial through the center of the stopper and direct the stream of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection, to the glass wall of the vial to avoid excessive foaming.
3. Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder. Do not vigorously shake or invert.
4. Allow the solution to sit for up to 20 minutes at room temperature to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within 30 minutes.
5. Visually inspect the reconstituted ENTYVIO solution for particulate matter and discoloration prior to dilution. Solution should be clear or opalescent, colorless to light brownish yellow and free of visible particulates. Do not administer reconstituted solution showing uncharacteristic color or containing particulates.
6. Once dissolved, gently invert vial three times.
7. Immediately, withdraw 5 mL (300 mg) of reconstituted ENTYVIO solution using a syringe with a 21- to 25- gauge needle. Discard any remaining portion of the reconstituted solution in the vial.

Dilution Instructions

Add the 5 mL (300 mg) of reconstituted ENTYVIO solution to 250 mL of 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection, and gently mix the infusion bag. Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Once reconstituted and diluted, use the infusion solution as soon as possible.

Discard any unused portion of the infusion solution.

Administration Instructions

After the infusion is complete, flush with 30 mL of 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection.

Storage and Stability

Specific storage conditions and timing for the reconstituted solution in vial and diluted solution in the infusion bag are outlined in Table 1.

Do not freeze the reconstituted solution in the vial or the diluted solution in the infusion bag.

The combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with 0.9% Sodium Chloride Injection, is a total of 12 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours refrigerated (2°C to 8°C [36°F to 46°F]). This combined storage time may include up to eight hours of the reconstituted solution in the vial at 2°C to 8°C.

The combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with Lactated Ringer's Injection, is a total of six hours refrigerated (2°C to 8°C [36°F to 46°F]).